The oncogenic roles of p53 mutants in mouse models

Current Opinion in Genetics and Development

Volumn 17, Issue 1, 2007, Pages 66-70

  Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73;

CARCINOGENESIS; CARCINOGENICITY; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; EMBRYO CELL; FIBROBLAST; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; IN VIVO STUDY; METASTASIS; MISSENSE MUTATION; MOUSE STRAIN; NONHUMAN; NULL ALLELE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; MICE; MUTATION, MISSENSE; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENES; PHENOTYPE; PHOSPHOPROTEINS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 33846243857     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2006.12.003     Document Type: Review

References (29)

1. Levine A.J., Momand J., and Finlay C.A. The p53 tumour suppressor gene. Nature 351 (1991) 453-456
2. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
3. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., Finlay C., and Levine A.J. Gain of function mutations in p53. Nat Genet 4 (1993) 42-46
4. Ko L.J., and Prives C. p53: puzzle and paradigm. Genes Dev 10 (1996) 1054-1072
5. Appella E., and Anderson C.W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268 (2001) 2764-2772
6. Haupt Y. p53 regulation: a family affair. Cell Cycle 3 (2004) 884-885
7. Sigal A., and Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60 (2000) 6788-6793
8. Zalcenstein A., Weisz L., Stambolsky P., Bar J., Rotter V., and Oren M. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25 (2006) 359-369
9. Weisz L., Zalcenstein A., Stambolsky P., Cohen Y., Goldfinger N., Oren M., and Rotter V. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 64 (2004) 8318-8327
10. Matas D., Sigal A., Stambolsky P., Milyavsky M., Weisz L., Schwartz D., Goldfinger N., and Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 20 (2001) 4163-4172
11. Moll U.M. The role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Clin Cancer Res 9 (2003) 5437-5441
12. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., and McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 2 (1998) 305-316
13. Jost C.A., Marin M.C., and Kaelin Jr. W.G. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389 (1997) 191-194
14. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
15. Fontemaggi G., Kela I., Amariglio N., Rechavi G., Krishnamurthy J., Strano S., Sacchi A., Givol D., and Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem 277 (2002) 43359-43368. The authors use expression arrays to list similarities and differences between p53 and p73 targets.
16. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., and Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002) 560-564
17. Mills A.A., Zheng B., Wang X.J., Vogel H., Roop D.R., and Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398 (1999) 708-713
18. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R.T., Tabin C., Sharpe A., Caput D., Crum C., et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398 (1999) 714-718
19. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
20. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., Yang A., McKeon F., and Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7 (2005) 363-373. Mice lacking one allele of both p63 and p73 develop a metastatic phenotype. Moreover, combinations of p63 or p73 heterozygosity with p53 heterozygosity also result in tumor metastasis.
21. Barbieri C.E., Tang L.J., Brown K.A., and Pietenpol J.A. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66 (2006) 7589-7597. This study complements in vivo experiments indicating a role for p63 loss in metastasis and identifies p63-specific targets by expression arrays.
22. Di Como C.J., Gaiddon C., and Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19 (1999) 1438-1449
23. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M., et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277 (2002) 18817-18826
24. Gaiddon C., Lokshin M., Ahn J., Zhang T., and Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21 (2001) 1874-1887. This is one of several studies that show the interactions of mutant p53 proteins with p63 and p73. Moreover, this study shows that the interactions occur through the DNA binding domain and that wild type p53 can bind only if it is denatured. This study implies that any alteration that exposes the DNA binding domain results in a p53 protein that interacts with p63 and p73.
25. Bensaad K., Le Bras M., Unsal K., Strano S., Blandino G., Tominaga O., Rouillard D., and Soussi T. Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J Biol Chem 278 (2003) 10546-10555
26. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25 (2000) 47-54
27. Strano S., Munarriz E., Rossi M., Cristofanelli B., Shaul Y., Castagnoli L., Levine A.J., Sacchi A., Cesareni G., Oren M., et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275 (2000) 29503-29512
28. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119 (2004) 861-872. A mutant p53 allele in vivo shows a metastatic phenotype, and embryo fibroblasts show increased growth and transformation potential. Mutant p53 can interact with p63 and p73 in tumor cells and inhibit their activities.
29. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., and Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119 (2004) 847-860. Two knock-in alleles at the p53 locus show tumor-specific differences and gain-of-function phenotypes in the 129Sv mouse strain.